41st Annual J.P. Morgan HEALTHCARE CONFERENCE

CEO and President Yaky Yanay and CFO Chen Franco-Yehuda will attend the event.

MIXiii | The Int’l Life Science & Health-Tech Week | November 9-10, 2022

Pluri’s CEO and President Yaky Yanay and CFO Chen Franco-Yehuda will attend the event

Events | A.G.P./Alliance Global Partners

Pluri’s CEO and President Yaky Yanay and CFO Chen Yehuda-Franco will attend the event

The Florida Family Office & Wealth Management Meeting (florida-wealth.com)

Pluri’s CEO and President Yaky Yanay and CFO Chen Franco-Yehuda will attend the event

Jefferies London Healthcare Conference 2022

Plur’s CFO Chen Yehuda-Franco will attend the event

64th ASH Annual Meeting & Exposition – Hematology.org

Pluri’s Medical Director, Dr. Michal Sheleg PhD, will be giving a poster presentation titled “Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities” on Monday, December 12, 2022 between 6:00-8:00pm

Challenges and Opportunities for MSCs (informaconnect.com)

Pluri’s CMO Dr. Nitsan Halevy and CTO Lior Raviv will be presenting during the event

CPHI Frankfurt

Pluri’s CCO Nimrod Bar Zvi and VP BD Efrat Kaduri will attend the event

Bio Europe 2022

Pluri’s VP BD Efrat Kaduri will attend the event

ESGCT 2022

Pluri’s CTO Lior Raviv, “Unleashing the Allogeneic Potential: Applying Separation Technologies in Large Scale Manufacture to Achieve Off the Shelf Products in Advanced Therapies”

©2023 Pluri Inc.

©2023 Pluri Inc., its logo, brand, product, and process names appearing in this issue are the trademarks of Pluri™ Inc. or its affiliated companies. All other brand, product, and process names appearing are the trademarks of their respective holders. Reference to or use of a product, or process other than those of Pluri™ Inc. does not imply recommendation, approval, affiliation, or sponsorship of that product, or process by Pluri™ Inc. Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right under any patent, copyright, trademark, or other intellectual property right of Pluri™ Inc. or any third party, except as expressly granted herein.  All information herein is for general information only and is subject for change without notice.

NAME

Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.